Evidence map›Paper›PMID 32405059›Full record

ArticleNature medicine2020

Author Correction: A Engineered immunogen binding to alum adjuvant enhances humoral immunity.

Tyson J Moyer, Yu Kato, Wuhbet Abraham, Jason Y H Chang, Daniel W Kulp, Nicki Watson, Hannah L Turner, Sergey Menis, Robert K Abbott, Jinal N Bhiman and 12 more

Open access · bronzeAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

22 authors at 5 institutions in 1 country.

Tyson J MoyerKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Yu KatoConsortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.
Wuhbet AbrahamKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Jason Y H ChangKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-2238-8232
Daniel W KulpConsortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.
Nicki WatsonWhitehead Institute of Biomedical Research, Cambridge, MA, USA.
Hannah L TurnerConsortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.
Sergey MenisConsortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.
Robert K AbbottConsortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.
Jinal N BhimanConsortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.
Mariane B MeloKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-0409-2454
Hayley A SimonDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA.
Sara Herrera-De la MataDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-9519-9520
Shu LiangDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA.
Gregory SeumoisDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-8164-6852
Yash AgarwalKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Na LiKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.
Dennis R BurtonConsortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0001-6711-9864
Andrew B WardConsortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.
William R SchiefConsortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-1120-0150
Shane CrottyConsortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA, USA.ORCID http://orcid.org/0000-0002-6484-6262
Darrell J IrvineKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA. djirvine@mit.edu.ORCID http://orcid.org/0000-0002-8637-1405
Scripps Research Institute · USLa Jolla Institute for Immunology · USMassachusetts Institute of Technology · USThe Wistar Institute · USWhitehead Institute for Biomedical Research · US

Funding

NovaSeq5000 High Throughput SequencerS10OD025052 · OD · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI SEUMOIS, GREGORY · 2018 to 2018
$832k
NIH HHS S10 OD025052
6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID32405059
PMCPMC7223225
OpenAlexW3017036400

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.